Safety and efficacy of ASP0367 in patients with primary mitochondrial myopathy
Full IRB Study Title:
A Randomized, Double-blind, Placebo-controlled Adaptive
Phase 2/3 Study with Open-label Extension to Assess the Efficacy, Safety and Tolerability of ASP0367 in Participants with Primary Mitochondrial Myopathy
IRB Study ID: 1713067
See complete study details here.
Study Sponsor:
Astellas Pharma, Inc.
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
Hilary Tonni, htonni@akronchildrens.org, 330-543-3193
Lead Investigator
Bruce H. Cohen, MD, FAAN
Chair, NeuroDevelopmental Science Center; Philip H. Maynard Chair in NeuroDevelopmental Science Fund; Chairman, American Academy of Neurology Advocacy Committee; Pediatric Neurologist
Pediatric Brain Tumor ProgramPediatric NeurologyMitochondrial Center